Island Pharmaceuticals Raises A$9m to Accelerate Galidesivir Biodefence Program and US Stockpile Push

The latest update is out from Island Pharmaceuticals Ltd ( (AU:ILA) ).

Island Pharmaceuticals has raised A$9 million via a placement of 25.7 million new shares at A$0.35 each, cornerstoned by a US-based family office and supported by other local and international investors, extending its cash runway from an existing A$6.87 million position. The funding will fully finance the two-stage Animal Rule development program and New Drug Application for its lead antiviral Galidesivir in Marburg virus, as well as manufacture additional drug supply and progress pre-clinical and regulatory work aimed at broader US Government Strategic National Stockpile opportunities in Ebola and Sudan virus. Management says the capital raise removes a key funding risk just as the FDA has provided clear alignment on Galidesivir’s development pathway, positioning Island to pursue potential US Government procurement and a valuable Priority Review Voucher, which together could unlock significant non-dilutive revenue streams and enhance shareholder value if the program succeeds.

The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.

More about Island Pharmaceuticals Ltd

Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on treatments aligned with US biodefence priorities. Its lead program is Galidesivir, an antiviral candidate being advanced under the US Food and Drug Administration’s Animal Rule pathway targeting high-consequence viral threats such as Marburg, Ebola and Sudan virus, with a view to potential inclusion in the US Government’s Strategic National Stockpile.

Average Trading Volume: 556,089

Technical Sentiment Signal: Buy

Current Market Cap: A$104.9M

See more data about ILA stock on TipRanks’ Stock Analysis page.